Tags

Type your tag names separated by a space and hit enter

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Gut. 2007 Apr; 56(4):553-9.Gut

Abstract

BACKGROUND

The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks.

AIM

To assess whether a shorter 16-week treatment is as effective as a standard 24-week treatment.

METHODS

Patients with HCV2 infection were randomised in a 1:2 ratio to either 16 weeks (n = 50) or 24 weeks (n = 100) of treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period. A rapid virological response (RVR) was defined as seronegative for HCV RNA at 4 weeks of treatment, and the primary end point, sustained virological response (SVR), as seronegative for HCV RNA at the 24-week follow-up.

RESULTS

The rate of RVR and SVR was 86% (43/50, 95% confidence interval (CI) 76% to 96%) and 94% (47/50, CI 87% to 100%), respectively, in the 16-week group, which was comparable to 87% (87/100, CI 80% to 94%) and 95% (95/100, CI 91% to 99%) in the 24-week group. Patients with RVR had a significantly higher SVR rate than patients without RVR in both 16-week (100% vs 57%, p = 0.015) and 24-week groups (98% vs 77%, p = 0.002). Multivariate analysis showed that RVR and age were independent factors associated with SVR. Both treatment arms were equally well tolerated. The incidence of alopecia was significantly higher in the 24-week group (49%) than in the 16-week group (20%, p = 0.001).

CONCLUSION

16 weeks and 24 weeks of peginterferon treatment with weight-based ribavirin at a dose of 1000-1200 mg/day provided equal efficacy in patients with HCV2 who achieved RVR at 4 weeks.

Authors+Show Affiliations

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16956917

Citation

Yu, Ming-Lung, et al. "A Randomised Study of Peginterferon and Ribavirin for 16 Versus 24 Weeks in Patients With Genotype 2 Chronic Hepatitis C." Gut, vol. 56, no. 4, 2007, pp. 553-9.
Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56(4):553-9.
Yu, M. L., Dai, C. Y., Huang, J. F., Hou, N. J., Lee, L. P., Hsieh, M. Y., Chiu, C. F., Lin, Z. Y., Chen, S. C., Hsieh, M. Y., Wang, L. Y., Chang, W. Y., & Chuang, W. L. (2007). A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut, 56(4), 553-9.
Yu ML, et al. A Randomised Study of Peginterferon and Ribavirin for 16 Versus 24 Weeks in Patients With Genotype 2 Chronic Hepatitis C. Gut. 2007;56(4):553-9. PubMed PMID: 16956917.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. AU - Yu,Ming-Lung, AU - Dai,Chia-Yen, AU - Huang,Jee-Fu, AU - Hou,Nai-Jen, AU - Lee,Li-Po, AU - Hsieh,Ming-Yen, AU - Chiu,Chang-Fu, AU - Lin,Zu-Yau, AU - Chen,Shinn-Cherng, AU - Hsieh,Ming-Yuh, AU - Wang,Liang-Yen, AU - Chang,Wen-Yu, AU - Chuang,Wan-Long, Y1 - 2006/09/06/ PY - 2006/9/8/pubmed PY - 2007/5/4/medline PY - 2006/9/8/entrez SP - 553 EP - 9 JF - Gut JO - Gut VL - 56 IS - 4 N2 - BACKGROUND: The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. AIM: To assess whether a shorter 16-week treatment is as effective as a standard 24-week treatment. METHODS: Patients with HCV2 infection were randomised in a 1:2 ratio to either 16 weeks (n = 50) or 24 weeks (n = 100) of treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period. A rapid virological response (RVR) was defined as seronegative for HCV RNA at 4 weeks of treatment, and the primary end point, sustained virological response (SVR), as seronegative for HCV RNA at the 24-week follow-up. RESULTS: The rate of RVR and SVR was 86% (43/50, 95% confidence interval (CI) 76% to 96%) and 94% (47/50, CI 87% to 100%), respectively, in the 16-week group, which was comparable to 87% (87/100, CI 80% to 94%) and 95% (95/100, CI 91% to 99%) in the 24-week group. Patients with RVR had a significantly higher SVR rate than patients without RVR in both 16-week (100% vs 57%, p = 0.015) and 24-week groups (98% vs 77%, p = 0.002). Multivariate analysis showed that RVR and age were independent factors associated with SVR. Both treatment arms were equally well tolerated. The incidence of alopecia was significantly higher in the 24-week group (49%) than in the 16-week group (20%, p = 0.001). CONCLUSION: 16 weeks and 24 weeks of peginterferon treatment with weight-based ribavirin at a dose of 1000-1200 mg/day provided equal efficacy in patients with HCV2 who achieved RVR at 4 weeks. SN - 0017-5749 UR - https://www.unboundmedicine.com/medline/citation/16956917/A_randomised_study_of_peginterferon_and_ribavirin_for_16_versus_24_weeks_in_patients_with_genotype_2_chronic_hepatitis_C_ L2 - http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=16956917 DB - PRIME DP - Unbound Medicine ER -